The Cystic Fibrosis Foundation awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in people with cystic fibrosis in a late phase clinical trial.
The Cystic Fibrosis Foundation awarded up to $4.7 million to EnBiotix Inc. to study the potential use of inhaled colistin as an additional option to treat Pseudomonas infections in people with cystic fibrosis who are not responding to current treatments.
| 2 min read
The treatment has the potential to prevent Aspergillus fungal infections in people who have had a lung transplant.
| 4 min read
Foundation to fund up to $110 million for collaboration to accelerate the development of genetic therapies for CF
| 4 min read
The Cystic Fibrosis Foundation supports universal masking in school to protect people with CF and other health conditions against COVID-19.
| 2 min read
The Cystic Fibrosis Lung Transplant Consortium Biorepository and Patient Registry, in collaboration with Cleveland Clinic, will provide critical clinical data and samples to support future research investigating complications of lung transplant.
| 4 min read
The Cystic Fibrosis Foundation announced the recipients of its sixth annual Impact Grants.
| 5 min read
Foundation welcomes new members to advance its mission
| 7 min read
The Cystic Fibrosis Foundation celebrates the decision issued by the United States Supreme Court in California v. Texas, ultimately protecting the Affordable Care Act.
| 3 min read